✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals
Market Cap
₹1,069 Cr.
P/E
12.99

Key Ratios

Market cap
Market cap
1,069 Cr
PE
PE
12.99
Prom Holding
Prom Holding
49.78 %
ROE (%)
ROE (%)
15.74
ROCE (%)
ROCE (%)
20.35
Div Yield (%)
Div Yield (%)
0.34
Sales
Sales
623 Cr
OPM (%)
OPM (%)
16.29 %
Debt to Equity
Debt to Equity
0.00
About
Lincoln Pharmaceuticals Ltd is engaged in the manufacture and marketing of affordable therapeu… Read more
Low
500
52W Range
High
975
  • Lincoln Pharma
  • Bharat Parenterals
  • Kwality Pharma
  • TJI Pharma

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statementNew
Edit rows
Forensics

7 Yes

Positive for this company

2 Neutral

Neutral for this company

8 No

Negative for this company

0 No Data

Insufficient data to analyse

Market Share
0.04 %
(as of Jul 22)
Anti - Diabetes - Market Share
0.15 %
(as of Jul 22)
Anti-Infectives - Market Share
0.80 %
(as of Nov 21)
Anti-Malarial - Market Share
0.10 %
(as of Nov 21)
Blood Related - Market Share
0.02 %
(as of Jul 22)
Cardiovascular - Market Share
0.11 %
(as of Nov 21)
Dermatology - Market Share
Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operational Metrics

    Select a Metric
    • Domestic Sales Growth - YoY (%)
    • R&D as a % of Total Sales (%)
    Peer Comparison
    Corporate Actions
    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less
    FAQs on Lincoln Pharmaceuticals Ltd. Business

    Lincoln Pharmaceuticals Ltd specializes in producing and promoting cost-effective therapeutic products such as Tablets, Capsules, Injectables, Syrups, and Ointments.

    Lincoln Pharma major competitors are Bharat Parenterals, Kwality Pharma, Anuh Pharma, Shivalik Rasayan, Wanbury, Kilitch Drugs(India), Ind-Swift Lab..
    Market Cap of Lincoln Pharma is ₹1,069 Crs.
    While the median market cap of its peers are ₹930 Crs.

    Lincoln Pharma seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    Company Filing
    Discussions & Analysis
    Ideas Dashboard
    Timeline
    Watchlist
    Portfolio
    Alerts
    Research
    Stock Screener
    Market
    Raw Material